Abstract
Paula Anastasia, RN, MN, AOCN®, of UCLA Health Medical Center, and Wendy H. Vogel, MSN, FNP, AOCNP®, of Harborside, discuss results from studies evaluating therapies in women with de novo metastatic breast cancer and HER2-positive breast cancer, along with targeted therapies for PIK3CA and ESR1 mutations. Reporting provided by The ASCO Post.
